文献速递冠心病血脂与心血管预防

C反应蛋白对高危血管病患者脂蛋白(a)相关心血管风险的影响:ACCELERATE试验预设二次分析

Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
PubMed 文献 · JAMA Cardiol · 2020-01-01

hsCRP<2 mg/L者无显著关联。提示残余炎症可能增强Lp(a)的致病风险。

要点

  • 高危血管病患者中,hsCRP≥2 mg/L时Lp(a)升高与心血管事件风险显著相关。
  • hsCRP<2 mg/L者中未观察到Lp(a)与心血管事件的显著关联。
  • log Lp(a)每增加1单位,hsCRP≥2 mg/L者心血管死亡、非致死性心梗或卒中风险增加13%。

核心结论

  • 在优化治疗的高危血管病患者中,Lp(a)升高仅当hsCRP≥2 mg/L时与心血管死亡、心梗和卒中相关,提示残余炎症可能调节Lp(a)相关风险。

研究设计与样本

  • 参与者接受evacetrapib 130 mg/d或安慰剂治疗。

临床怎么用

  • 对高危血管病患者,可考虑同时评估hsCRP和Lp(a)以识别残余炎症背景下Lp(a)相关风险增高者。
  • hsCRP≥2 mg/L且Lp(a)升高的患者可能从Lp(a)降低治疗中获益,但需进一步研究验证。

局限性

  • 本研究为事后二次分析,结论需前瞻性研究验证。
  • 研究使用evacetrapib,未显示对30个月主要不良心血管事件有显著获益或危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although lipoprotein(a) (Lp[a]) is a causal genetic risk factor for atherosclerotic cardiovascular disease, it remains unclear which patients with established atherosclerotic cardiovascular disease stand to benefit the most from Lp(a) lowering. Whether inflammation can modulate Lp(a)-associated cardiovascular (CV) risk during secondary prevention is unknown. OBJECTIVE: To examine whether Lp(a)-associated CV risk is modulated by systemic inflammation in optimally treated patients at high risk of CV disease. DESIGN, SETTING, AND PARTICIPANTS: A prespecified secondary post hoc analysis of the double-blind, multicenter randomized clinical Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) trial was conducted between October 1, 2012, and December 31, 2013; the study was terminated October 12, 2015. The study was conducted at 543 academic and community hospitals in 36 countries among 12 092 patients at high risk of CV disease (acute coronary syndrome, stroke, peripheral arterial disease, or type 2 diabetes with coronary artery disease) with measurable Lp(a) and high-sensitivity C-reactive protein (hsCRP) levels during treatment. Statistical analysis for this post hoc analysis was performed from September 26, 2018, to March 28, 2020. INTERVENTIONS: Participants received evacetrapib, 130 mg/d, or matching placebo. MAIN OUTCOMES AND MEASURES: The ACCELERATE trial found no significant benefit or harm of evacetrapib on 30-month major adverse cardiovascular events (CV death, myocardial infarction [MI], stroke, coronary revascularization, or hospitalization for unstable angina). This secondary analysis evaluated rates of CV death, MI, and stroke across levels of Lp(a). RESULTS: High-sensitivity C-reactive protein and Lp(a) levels were measured in 10 503 patients (8135 men; 8561 white; 10 134 received concurrent statins; mean [SD] age, 64.6 [9.4] years). In fully adjusted analyses, in patients with hsCRP of 2 mg/L or more but not less than 2 mg/L, increasing quintiles of Lp(a) were significantly associated with greater rates of death, MI, and stroke (P = .006 for interaction). Each unit increase in log Lp(a) levels was associated with a 13% increased risk of CV death, nonfatal MI, or stroke only in those with hsCRP levels of 2 mg/L or more (P = .008 for interaction). There was also a significant stepwise relationship between increasing Lp(a) quintiles and time to first CV death, MI, or stroke (log-rank P < .001) when hsCRP levels were 2 mg/L or more but not less than 2 mg/L. Sensitivity analyses in the ACCELERATE placebo-treated group yielded similar significant associations exclusively in the group with hsCRP of 2 mg/L or more. CONCLUSIONS AND RELEVANCE: Elevated Lp(a) levels during treatment are related to CV death, MI, and stroke when hsCRP levels are 2 mg/L or more but not less than 2mg/L. This finding suggests a potential benefit of lowering Lp(a) in patients with residual systemic inflammation despite receipt of optimal medical therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01687998.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Puri R, Nissen SE, Arsenault BJ, et al. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. JAMA Cardiol. 2020. PMID: 32639518. doi:10.1001/jamacardio.2020.2413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。